Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer

Completed · Phase 1/Phase 2

Conditions studied: Extensive-Stage Small-Cell Lung Cancer

In brief

The purpose of this study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib given in combination with carboplatin and etoposide as initial therapy for patients with extensive-stage small-cell lung cancer (ES SCLC).

Key facts

Study ID
NCT01987232
Run by
Amgen
People needed
32
Starts
2013-11-05
Expected to finish
2017-05-04
Last updated by the study team
2017-08-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.